

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

Complete if Known	
Application Number:	09/777,526
Filing Date:	February 6, 2001
First Named Inventor:	Agrawal, et al.
Art Unit:	1635
Examiner Name:	Terra C. Gibbs
Attorney Docket Number:	HYZ-030CPCN347508.518

U. S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

Examiner Signature	<i>[Signature]</i>	Date Considered	2/21/05
-----------------------	--------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
A collection of information unless it contains a valid PMS control number.

(7) Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

of 1

Complete if Known	
Application Number	09/777,526
Filing Date	February 6, 2001
First Named Inventor	Agrawal, et al.
Art Unit	1635
Examiner Name	Terra C. Gibbs
Attorney Docket Number	HYZ-030CPCN3.47508.5

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature *Susan G. O.* **Date Considered** *2/24/05*

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
IN AN APPLICATION**
(Use several sheets if necessary)

MAY 2 2001

1205

PATENT & TRADEMARK OFFICE

Docket Number HYZ-030CPNCN3	Application Number 09/777,526
Applicant Agrawal et al.	
Filing Date February 6, 2001	Group Art Unit 1635

Sheet 1 OF 4

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SJL	4,309,404	1/5/1982	DeNeale et al.	424	21	
	4,309,406	1/5/1982	Guley et al.	424	21	
	4,556,552	12/3/1985	Porter et al.	424	32	
	4,704,295	11/3/1987	Porter et al.	427	3	
	5,220,007	6/15/1993	Pederson et al.	536	23.1	
	5,149,797	9/22/1992	Pederson et al.	536	23.1	
	5,220,007	12/21/1993	Cho-Chung	424	450	MAY 23 2001
	5,248,670	9/28/1993	Draper et al.	514	44	
	5,271,941	12/21/1993	Cho-Chung	424	450	TECH CENTER 1600/2900
	5,403,709	10/6/1992	Agrawal et al.	435	6	
	5,442,049	8/15/1995	Anderson et al.	536	24.5	
	5,470,967	11/28/1995	Huie et al.	536	24.3	
	5,514,577	5/7/1996	Draper et al	435	238	
	5,578,716	12/1/1993	Szyt et al.	536	24.5	
	5,612,212	11/12/1993	Gewirtz	435	456	
	6,143,881	11/7/2000	Metelev et al.	536	24.5	
	5,652,355	7/29/1997	Metelev et al.	536	24.5	
	5,969,117	10/19/1999	Agrawal	536	22.1	

RECEIVED

MAY 23 2001

TECH CENTER 1600/2900

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
SJL	94/02498	2/3/1994	WO	C07H 21	00		X
VCL	94/15619	7/21/1994	WO	A61K 31	70		X

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

<i>SJL</i>	A1	Agrawal, Sudhir, "Functionalization of oligonucleotides with amino groups and attachment of amino specific reporter groups." <i>Methods Mol Biol.</i> , Vol. 26, pp. 93-120 (1994)
<i>SJL</i>	A2	Agrawal et al., "Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues." <i>Proc Natl Acad Sci U S A.</i> , Vol. 86, No. 20, pp. 7790-4 (1989)
<i>SJL</i>	A3	Agrawal, <u>Antisense Therapeutics</u> . (Sudhir Agrawal, ed.) , Page V (1996)

EXAMINER

Levin

DATE CONSIDERED

3/1/05

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

OPI INFORMATION DISCLOSURE
IN AN APPLICATION

MAY 21 2001 (Use several sheets if necessary)

PATENTS & TRADEMARKS
Sheet 1 of 2

2 OF 4

Docket Number
HYZ-030CPCN3Application Number
09/777,526Applicant
Agrawal et al.RECEIVED
MAY 23 2001

TECH CENTER 1600/290

Filing Date
February 6, 2001Group Art Unit
1635

- pp*
- | | |
|-----|--|
| A4 | Agrawal et al., "Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides." <i>Proc Natl Acad Sci U S A.</i> , Vol. 87, No. 4, pp. 1401-5 (1990) |
| B1 | Agrawal et al., "Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice." <i>Proc Natl Acad Sci U S A.</i> , Vol. 88, No. 17, pp. 7595-9 (1991) |
| B2 | Agrawal et al., "Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration." <i>Biochem Pharmacol.</i> , Vol. 50, No. 4, pp. 571-6 (1995) |
| B3 | Agrawal et al., "Antisense oligonucleotides as antiviral agents." <i>Trends in Biotechnol.</i> , Vol. 10, pp. 152-158 (1992) |
| B4 | Agrawal et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus." <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 85, pp. 7079-7083 (1988) |
| B5 | Agrawal, S., "History of Antisense Oligonucleotides" in <i>Antisense Therapeutics</i> (Sudhir Agrawal ed.), Human Press, Totowa, New Jersey (1996) |
| B6 | Craig et al., <i>Exp. Opin. Ther. Patents</i> 7:1175-1182 (1997) |
| B7 | Bayever et al., "Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial." <i>Antisense Res Dev.</i> Vol. 3, No. 4, pp. 383-90 (1993) |
| B8 | Boutorine et al, <i>Biochimie</i> 76: 23-32 (1994) |
| B9 | Ceruzzi et al., <i>Nucleosides and Nucleotides</i> 8 (5&6): 815-8 (1989) |
| B10 | Egli et al. (10/8-9/98) <i>Antisense 98, Targeting the Molecular Basis of Disease</i> , pp. 37 |
| B11 | Furdon et al., "RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds." <i>Nucleic Acids Res.</i> , Vol. 17, No. 22, pp. 9193-204 (1989) |
| B12 | Galderisi et al., "Antisense oligonucleotides as therapeutic agents." <i>J. Cell. Physiol.</i> , Vol. 181, pp. 251-57 (1999) |
| B13 | Hughes et al., "Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs." <i>Pharm Res.</i> , Vol. 6, pp. 817-24. (1995) |
| B14 | Isis Pharmaceuticals -Press Release 060500, June 5 (2000) |
| B15 | Isis Pharmaceuticals, Inc., <i>Antisense 97: Targeting the Molecular Basis of Disease</i> , Nature Biotechnology Conference, May 1-2 1997 |
| B16 | International Business Communications, IBC's Fourth Annual International Symposium on Oligonucleotides and Gene Therapy-Based Antisense Therapeutics with New Applications for Genomics, February 6-7 1997 |
| B17 | International Business Communications, IBC's Sixth Annual International Conference on Oligo-Therapeutics, Molecular Tools and Novel Therapeutic Strategies, May 1999 |
- pp*

EXAMINER

DATE CONSIDERED

3/1/05

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

**INFORMATION DISCLOSURE
IN AN APPLICATION**

MAY 21 2001
(Use several sheets if necessary)

Docket Number	HYZ-030CPCN3	Application Number	09/777,526
Applicant	Agrawal et al.	MAY 23 2001	RECEIVED
Filing Date	February 6, 2001	Group	TECH CENTER 1600/2000 1635

3. OF 4

B17	Inoue et al., "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H." <i>FEBS Lett.</i> , Vol. 215, No. 2, pp. 327-30 (1987)
B18	Inoue et al., <i>FEBS Lett.</i> , Vol. 215, pp. 237-250 (1987)
B19	Iversen, "In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue." <i>Anticancer Drug Des.</i> , Vol. 6, No. 6, pp. 531-8 (1991)
C1	Iversen, "Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion." <i>Antisense Res Dev.</i> , Vol. 4, No. 1, pp. 43-52 (1994)
C2	Kawasaki et al., "Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets." <i>J Med Chem.</i> , Vol. 36, No. 7, pp. 831-41 (1993)
C3	Levin (10/8-9/98) <i>Antisense 98: Targeting the Molecular Basis of Disease</i> , pp. 25
C4	Martin, P. <i>Helvetica Chimica Acta</i> , 78: 486-504 (1995)
C5	Metelev et al., <i>Bioorganic & Medicinal Chemistry Letters</i> , 4: 2929-2934 (1994)
C6	Milligan et al., "Current concepts in antisense drug design." <i>J Med Chem.</i> , Vol. 36, No. 14, pp. 1923-37 (1993)
C7	Orr, (Reported By) <i>Antisense 98: Targeting the Molecular Basis of Disease (Part III)</i> " Organized by Nature Biology, London, UK (1988)
C8	Quartin et al., "Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates." <i>Nucleic Acids Res.</i> , Vol. 17, No. 18, pp. 7253-62 (1989)
C9	Rapaport et al., "Antimalarial activities of oligodeoxynucleotide phosphorothioates in chloroquine-resistant Plasmodium falciparum." <i>Proc Natl Acad Sci U S A</i> , Vol. 89, No. 18, pp. 8577-80 (1992)
C10	Sands, "Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate." <i>Mol Pharmacol.</i> , Vol. 45, No. 5, pp. 932-43 (1994)
C11	Shibahara et al., "Site-directed cleavage of RNA." <i>Nucleic Acids Res.</i> , Vol. 15, No. 11, pp. 4403-15 (1987)
C12	Shibahara et al., "Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives." <i>Nucleic Acids Res.</i> , Vol. 17, No. 1, pp. 239-52 (1989)
C13	Shibahara et al., <i>Nucleic Acids Res.</i> , Vol. 15, pp. 4403-4415 (1987)
C14	Sonneaux, "Protecting Groups in Oligonucleotide Synthesis", in <i>Methods in Molecular Biology</i> (Agrawal ed.) 26:1-71 (1994)
C15	Stein et al., "Antisense oligonucleotides as therapeutic agents—is the bullet really magical?" <i>Science</i> , Vol. 261, No. 5124, pp. 1004-12 (1993)
C16	Takashima et al., "Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity." <i>Proc Natl Acad Sci U S A</i> , Vol. 90, No. 16, pp. 7789-93 (1993)
C17	Tidd et al., "Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups." <i>Br J Cancer.</i> , Vol. 60, No. 3, pp. 343-50 (1989)

EXAMINER	DATE CONSIDERED
<i>Rina Bell</i>	3/1/05

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not conformance and not considered. Include copy with next communication to applicant.

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

MAY 21 2001

Sheet 1

4

OF

4

Docket Number
HYZ-030CPCN3Application Number
09/777,526Applicant
Agrawal et al.Filing Date
February 6, 2001Group Art Unit
1635

<i>P.J.</i>	C18	Tortora et al., "Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production." <i>Clin Cancer Res.</i> Vol. 6, No. 6, pp. 2506-12 (2000)
	C19	Tseng et al., "Antisense oligonucleotide technology in the development of cancer therapeutics." <i>Cancer Gene Ther.</i> , Vol. 1, pp. 65-71 (1994)
	C20	Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle" <i>Chem. Rev.</i> Vol. 90, pp. 543-584 (1990)
	D1	Wang et al., "Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the R1alpha subunit of protein kinase A after oral administration." <i>Proc Natl Acad Sci U S A.</i> , Vol. 96, No. 24, pp. 13989-94 (1999)
	D2	Wickstrom, E., "Oligodeoxynucleotide stability in subcellular extracts and culture media." <i>J Biochem Biophys Methods.</i> , Vol. 13, No. 2, pp. 97-102. (1986)
	D3	Wickstrom, E., "Strategies for administering targeted therapeutic oligodeoxynucleotides." <i>Trends Biotechnol.</i> , Vol. 10, No. 8, pp. 281-7(1992)
	D4	Zamecnic, P., "History of Antisense Oligonucleotides" in <i>Antisense Therapeutics</i> (Sudhir Agrawal ed.), Human Press, Totowa, New Jersey (1996) pp. 1-11.
	D5	Zhao et al., <i>Antisense Res. and Dev.</i> 3: 53-66 (1993)
	D6	Zon, <i>Pharm. Res</i> 5(9): 539-49 (1988)
<i>P.J.</i>	D7	Zendegui et al., "In vivo stability and kinetics of absorption and disposition of 3' phosphopropyl amine oligonucleotides." <i>Nucleic Acids Res.</i> , Vol. 20, No. 2, pp. 307-14 (1992)

RECEIVED
MAY 23 2001
TECH CENTER 1600/2900

EXAMINER

Rita H. Hall

DATE CONSIDERED

3/1/05

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609. Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.